Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jin Yin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Salvage Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Research Fund of Tongji Hospital, Natural Scinence Foundation of Hubei Province.
Abstract (Originalsprache)
Backgroud The high cost of blinatumomab in full doses of full treatments has led to dose reduction and fewer treatment cycles for most patients in China. With current needs for cost‐efficiency and resource management in health care, we retrospectively evaluated the clinical effects of short‐course blinatumomab treatment for R/R Ph‐ B‐ALL at our center.
Methods
Blinatumomab was administered with 24‐h continuous intravenous infusion (9 μg/day for the first 3 days and 28 μg/day for 6–10 days). The clinical data of 30 R/R B‐ALL patients were collected and analyzed.
Results
A total of 25 patients (83.3%) including 13 (43.3%) with a high leukemic load (> 50%) achieved morphological CR. Twelve patients (40%) were MRD‐negative. The estimated 2‐year OS rate was 82.62%. The 2‐year PFS rate was 78.35%. The estimated 2‐year OS and PFS were significantly better in patients receiving further treatment.
Conclusions
Our findings provide novel insights into the optimization of blinatumomab therapy, proposing a viable treatment alternative that aligns with current needs for cost‐efficiency and resource management in health care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Jin Yin, Bingxin Qian
Förderung
- National Natural Science Foundation of China
- Research Fund of Tongji Hospital
- Natural Scinence Foundation of Hubei Province
- Beijing Xisike Clinical Oncology Study Foundation
Zitieren
APA
Yin, J., Cai, X., Qian, B., Liu, Y., & Li, D. (2024). Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study. Cancer Medicine. https://doi.org/10.1002/cam4.70515
Vancouver
Yin J, Cai X, Qian B, Liu Y, Li D. Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study. Cancer Medicine. 2024. doi:10.1002/cam4.70515
BibTeX
@article{Yin2024,
author = {Yin, Jin and Cai, Xiaoya and Qian, Bingxin and Liu, Ying and Li, Dengju},
title = {Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70515}
}
EUVIMED